Private Equity in Indian Healthcare 2026: Deal Trends, Valuations, and What Exits Actually Look Like

Where the Capital Goes

Hospitals (the anchor theme): multispecialty platforms, brownfield roll-ups, and single-specialty chains with proven unit economics — oncology, IVF, ophthalmology, mother-and-child, nephrology. The logic: scarce accredited capacity, insurance-driven volume growth, consolidation runway, and demonstrated exits. The consequence: entry multiples for quality assets have expanded to the high teens and beyond on EV/EBITDA. Pharma services (the momentum theme): CDMO/CRDMO platforms riding global supply-chain diversification from China — strategic logic is sound; competitive auctions have priced much of the thesis upfront. Diagnostics: steady, cash-generative, but post-COVID normalisation has tempered earlier exuberance. Digital health (the reckoning): billions absorbed in 2020–22; funding has since compressed sharply as unit economics failed to follow revenue.

The Valuation Problem, Stated Plainly

Healthcare's defensive growth story is precisely why it is expensive. Listed hospital chains trade at premium multiples, and private transactions for quality platforms have matched or exceeded them. Underwriting at these entry points requires believing some combination of: sustained mid-teens EBITDA growth, further multiple expansion at exit, and no adverse tariff or regulatory event across the hold. Each is possible; the conjunction is optimistic. The arithmetic every IC knows but deal momentum discounts: at high-teens entry multiples, operational value creation must do all the work — and healthcare operations improve slowly.

The Exit Record: Read It Before Repeating the Thesis

Indian healthcare PE cites a handful of genuinely excellent outcomes — large hospital platform sales to global buyers and sovereign capital, IPOs of hospital and diagnostics chains, and secondary sales between funds. These are real. But the distribution matters: marquee exits are concentrated in a small number of assets, secondary sales between financial sponsors increasingly dominate exit routes (which recycles risk rather than realising the thesis with strategic or public buyers), and the digital-health vintage of 2020–22 will, in aggregate, return well below cost. The honest scorecard: hospital and pharma-services PE in India has worked for disciplined early movers; the marginal dollar entering today buys the same thesis at twice the price.

What LPs and Promoters Should Each Take from This

For investors: the durable playbook remains buy-and-build below platform multiples — regional hospital assets, single-specialty roll-ups, diagnostics bolt-ons — where entry discipline is still possible, paired with genuine operating capability (payer-mix management, clinical talent retention, throughput). Auction-won platform deals at peak multiples are participation, not alpha. For promoters: this is a seller's market for quality assets, and the window is defined by capital supply, not by your P&L alone. Preparation — audited clinical and financial data, payer-mix clarity, talent lock-ins, clean related-party structures — routinely moves outcomes by turns of EBITDA. The gap between prepared and unprepared sellers has never priced wider.

Frequently Asked Questions

Related Insights